Identification of a serum biomarker signature associated with metastatic prostate cancer

Venera Kuci Emruli, Leena Liljedahl, Ulrika Axelsson, Corinna Richter, Lisa Theorin, Anders Bjartell, Hans Lilja, Jenny Donovan, David Neal, Freddie C. Hamdy, Carl A.K. Borrebaeck

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review


Purpose: Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over-treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease. Experimental design: In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non-metastatic PC and patients with metastatic PC, using a recombinant antibody microarray. Results: A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified. Conclusions and clinical relevance: The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.

TidskriftProteomics - Clinical Applications
Tidigt onlinedatum2021
StatusPublished - 2021 maj 1

Ämnesklassifikation (UKÄ)

  • Cancer och onkologi


Utforska forskningsämnen för ”Identification of a serum biomarker signature associated with metastatic prostate cancer”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här